triocean | Adobe Stock
The U.S. Food & Drug Administration (FDA) approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages 1 through 3 years with a confirmed diagnosis of peanut allergy to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.
Palforzia has been approved since January 2020 for initiation of treatment in individuals ages 4 through 17 years with a confirmed diagnosis of peanut allergy with up-dosing and maintenance in individuals 4 years of age and older.
Those who take Palforzia must continue to avoid peanuts in their diets. A Risk Evaluation and Mitigation Strategy (REMS) is in place for Palforzia to mitigate the risk of anaphylaxis associated with Palforzia, which includes elements to assure safe use.
Latest from Quality Assurance & Food Safety
- Food Industry Launches Public-Private Partnership to Advance Food Traceability
- University of Missouri’s Christopher Daubert Takes Over as President of IFT
- SIMBA Traceability Gets New Feature: One-Step Receiving Process by Scanning Existing Barcode Label
- USDA’s Economic Research Service Publishes 2023 Household Food Security in the U.S. Report
- Natural Grocers Announces Partnership with Rodale Institute to Help Grow Regenerative Organic Agriculture Movement
- Agmatix Launches RegenIQ to Drive Adoption of Regenerative Agriculture
- First Wrongful Death Lawsuit Filed as Death Count Rises in Boar's Head Listeria Outbreak
- Kebab Franchise to Roll Out Up To 2,400 Autonomous Food Robots
